Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 12:14 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 120 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Healthy Elderly Subjects Clear all

Conditions: Healthy
Interventions: Lasmiditan, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 65 Years and older
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 2
States / cities: Daytona Beach, Florida • Madison, Wisconsin

Conditions: Alzheimer's Disease
Interventions: BPN14770, Placebo; Drug
Lead sponsor: Tetra Discovery Partners; Industry
Eligibility: 25 Years to 90 Years
Enrollment: 77 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Kalamazoo, Michigan

Conditions: Healthy Elderly
Interventions: PF-06743649, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 65 Years to 85 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 2
States / cities: South Miami, Florida

Conditions: Healthy Young Volunteers, Healthy Elderly Volunteers
Interventions: AZD3293, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Healthy, Elderly
Interventions: PF-04447943; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 65 Years to 85 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Erectile Dysfunction
Interventions: Tamsulosin and avanafil, Doxazosin and avanafil; Drug
Lead sponsor: VIVUS LLC; Industry
Eligibility: 40 Years to 65 Years · Male only
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Herpes Simplex
Interventions: GSK208141, Havrix (investigational formulation), Placebo; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 10 Years to 17 Years · Female only
Enrollment: 5,960 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2007
U.S. locations: 66
States / cities: Birmingham, Alabama • Chandler, Arizona • Mesa, Arizona + 54 more

Conditions: Healthy Volunteers, Pharmacokinetics of ASP1941
Interventions: ASP1941, Placebo; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 65 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Miramar, Florida

Conditions: Influenza
Interventions: MF59-eH1N1_f; Biological
Lead sponsor: Novartis; Industry
Eligibility: 18 Years and older
Enrollment: 2,719 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 20
States / cities: Miami, Florida • Lenexa, Kansas • Omaha, Nebraska + 16 more

Conditions: Healthy
Interventions: ExPEC4V, Placebo; Biological
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 2
States / cities: Wichita, Kansas • Knoxville, Tennessee

Conditions: Healthy
Interventions: GSI-953; Drug
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer; Industry
Eligibility: 65 Years and older
Enrollment: 49 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Healthy
Interventions: PF-04447943, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 17 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Glendale, California

Conditions: Alzheimer's Disease
Interventions: TC-5619, Placebo; Drug
Lead sponsor: Targacept Inc.; Industry
Eligibility: 55 Years to 80 Years
Enrollment: 38 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 10
States / cities: Long Beach, California • San Francisco, California • Hallandale, Florida + 7 more

Conditions: Age Related Cognitive Decline, Age Related Macular Degeneration
Interventions: Walnuts, habitual diet; Dietary Supplement · Other
Lead sponsor: Loma Linda University; Other
Eligibility: 63 Years to 79 Years
Enrollment: 708 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Loma Linda, California

Conditions: Infections, Meningococcal
Interventions: Meningococcal vaccine GSK 134612, Menactra®; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 10 Years to 25 Years
Enrollment: 1,013 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 24
States / cities: Chandler, Arizona • Paramount, California • Sacramento, California + 19 more

Conditions: Healthy Adults
Interventions: methylnaltrexone, placebo; Drug
Lead sponsor: Bausch Health Americas, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006
U.S. locations: 1
States / cities: Tarrytown, New York

Conditions: Healthy Adults, Elderly Subjects
Interventions: TD-0714, Placebo; Drug
Lead sponsor: Theravance Biopharma; Industry
Eligibility: 19 Years to 80 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Healthy, Elderly
Interventions: Lactobacillus rhamnosus GG ATCC 53103 (LGG), Placebo; Biological
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 65 Years to 80 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Constipation
Interventions: TD-1211 Dose 1, TD-1211 Dose 2; Drug
Lead sponsor: Glycyx Therapeutics; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 47 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Influenza
Interventions: Influenza Virus Vaccine USP Trivalent Types A and B; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 1,250 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 44
States / cities: Hoover, Alabama • Huntsville, Alabama • Mobile, Alabama + 38 more

Conditions: Tetanus, Diphtheria, Pertussis, Whooping Cough
Interventions: Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed Formulation 1, Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed, Formulation 2, Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed, Formulation 3, Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed, Formulation 4, Licensed Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed, Licensed Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 10 Years and older
Enrollment: 1,363 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 20
States / cities: Birmingham, Alabama • Fayetteville, Arkansas • Jonesboro, Arkansas + 16 more

Conditions: Tolerability, Healthy, Elderly
Interventions: AZD9742, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 65 Years and older
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: Springfield, Missouri

Conditions: Healthy, Non-Smoking
Interventions: varenicline, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 65 Years to 85 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 2
States / cities: Miami, Florida • Orlando, Florida

Conditions: CNS
Interventions: E2006, Placebo comparator; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 2
States / cities: Culver City, California • Glendale, California

Search by objective public record fields.

A Study of Lasmiditan in Healthy Elderly Participants

A Multiple Ascending Dose Study of BPN14770 in Healthy Young and Elderly Male or Female Subjects

A Study In Healthy Elderly People To Evaluate Safety, Toleration, Pharmacokinetics and Pharmacodynamics of Multiple Oral Doses Of PF-06743649

A Single Dose Study to Assess the Safety, Effects, and Blood and Urine Drug Levels of AZD3293 in Healthy Subjects

A Study to Evaluate Safety, Tolerability, Plasma Drug Levels, and Cognitive Response Following Multiple Doses of a Drug in Healthy Elderly Participants.

Hemodynamic Study of Avanafil and Two α-Adrenergic Blockers,Doxazosin and Tamsulosin

Safety Study of Herpes Simplex Vaccine in HSV Seronegative and Seropositive Females Between 10 and 17 Years Old

Study of the Pharmacokinetics of ASP1941 and the Effect on Glucose Concentrations in Male and Female Young and Elderly Healthy Adults

Safety and Immunogenicity of A/H1N1-SOIV (Swine Flu) Vaccine With and Without Adjuvant in Non-Elderly and Elderly Adults

A Study to Evaluate Safety and Immunogenicity of the ExPEC4V Clinical Trial Material After a Single Intramuscular Dose and a Second Dose 6 Months Later in Healthy Participants Aged 18 Years and Older

Study Evaluating Multiple Doses Of GSI-953 Within The Elderly Population

Study Of Single Ascending And Multiple Doses Of PF-04447943 In Japanese Subjects.

Multiple Ascending Dose Study of TC-5619 in Healthy Elderly Subjects and Subjects With Alzheimer's Disease

Walnuts and Healthy Aging

Immunogenicity and Safety Study of GSK Biologicals' Meningococcal Vaccine GSK 134612 Versus Menactra® in Healthy Adolescents/Adults

Study of Pharmacokinetics, Safety and Tolerability of Intravenous Methylnaltrexone Bromide

Multiple Ascending Dose Study of TD-0714 in Healthy and Elderly Subjects

Safety of Lactobacillus Rhamnosus GG Vs. Placebo in Elderly Subjects Receiving Trivalent Inactivated Influenza Vaccine

TD-1211 Single-Dose Study in Elderly and Young Healthy Subjects

Study of Influenza Vaccine Revaccination in Healthy Adults Previously Vaccinated With Fluzone ID or Fluzone IM

Study of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed in Healthy Subjects

Assessing the Safety and Tolerability of a Single IV Dose of AZD9742 in Healthy Elderly Male and Female Subjects

Evaluation of Varenicline Safety, Tolerability, Pharmacokinetics and Pro-Cognitive Effects in Healthy Elderly Non-Smoking Subjects

2-Part Multiple Ascending Dose Study for Safety and Pharmacokinetics in Healthy and Elderly Subjects